- ISIN
- US68621F1021
- CUSIP
- 68621F102
- Sector
- Healthcare
- IPO Date
- Jan 5, 2017
Highlights
- Market Cap
- $310.55M
- Enterprise Value
- $299.75M
- EPS (TTM)
- -$0.00
- Total Revenue (TTM)
- $514.48M
- Gross Profit (TTM)
- $356.44M
- EBITDA (TTM)
- $24.36M
- Year Range
- $2.04 - $7.08
- Target Price
- $9.00
- ROA (TTM)
- -0.05%
- ROE (TTM)
- -0.12%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ORGO Performance Chart
Organogenesis Holdings Inc. (ORGO) is down 53.1% since the beginning of the year. At $2 per share, ORGO is trading 65.7% below its 52-week high of $7. Investors who bought $1,000 worth of ORGO shares 5 years ago would now be looking at an investment worth $145.
Loading charts...
Returns By Period
Organogenesis Holdings Inc. (ORGO) has returned -53.09% so far this year and -24.77% over the past 12 months.
Organogenesis Holdings Inc.
- 1D
- -0.41%
- 1M
- -8.65%
- YTD
- -53.09%
- 6M
- -57.44%
- 1Y
- -24.77%
- 3Y*
- -10.77%
- 5Y*
- -32.07%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ORGO Monthly Returns History
Based on dividend-adjusted daily data since Jan 5, 2017, ORGO's average daily return is +0.23%, while the average monthly return is +0.99%. At this rate, an investment would double in approximately 5.9 years.
Historically, 45% of months were positive and 55% were negative. The best month was May 2023 with a return of +77.1%, while the worst month was Feb 2019 at -51.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.
On a daily basis, ORGO closed higher 41% of trading days. The best single day was Jan 9, 2019 with a return of +512.7%, while the worst single day was Jan 17, 2019 at -59.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -22.78% | -19.75% | -26.17% | -0.84% | 9.36% | -5.45% | -53.09% | ||||||
| 2025 | 15.00% | 68.75% | -30.43% | 13.66% | -44.20% | 33.58% | 26.23% | 11.47% | -18.06% | 0.71% | 21.88% | 0.00% | 61.87% |
| 2024 | -19.32% | 8.18% | -20.45% | -17.25% | 17.02% | 1.82% | 7.86% | -4.64% | -0.69% | -3.15% | 39.71% | -17.31% | -21.76% |
| 2023 | -4.83% | -4.30% | -13.06% | -3.76% | 77.07% | -8.54% | 28.61% | -34.43% | 13.57% | -29.56% | 13.84% | 60.39% | 52.04% |
| 2022 | -16.77% | -3.25% | 2.42% | -15.49% | -12.89% | -13.01% | 17.62% | -37.46% | -9.75% | 1.23% | -16.46% | -1.82% | -70.89% |
| 2021 | 38.91% | 45.41% | 19.79% | 22.72% | -20.26% | -6.79% | -7.70% | 11.21% | -16.53% | -22.89% | -8.38% | -8.15% | 22.71% |
Benchmark Metrics
Organogenesis Holdings Inc. has an annualized alpha of 49.64%, beta of 1.23, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since January 05, 2017.
- This stock participated in 167.34% of S&P 500 Index downside but only 63.17% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 49.64%
- Beta
- 1.23
- R²
- 0.01
- Upside Capture
- 63.17%
- Downside Capture
- 167.34%
Return for Risk
Risk / Return Rank
ORGO ranks 30 for risk / return — below 30% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Organogenesis Holdings Inc. (ORGO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ORGO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.36 | ||
| Sortino ratioReturn per unit of downside risk | -2.79 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.37 | -0.37 |
| Calmar ratioReturn relative to maximum drawdown | -0.38 | 2.78 | -3.16 |
| Martin ratioReturn relative to average drawdown | -0.63 | 12.44 | -13.07 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Organogenesis Holdings Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Organogenesis Holdings Inc. was 98.74%, occurring on Mar 24, 2023. The portfolio has not yet recovered.
The current Organogenesis Holdings Inc. drawdown is 98.38%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -98.74%Mar 2023 | 4y 2mo | — | 7y 5moJan 2019 - now |
Rate-hike selloffLate 2018 | -6.43%Oct 2018 | 13d | 4d | 17dOct 2018 - Oct 2018 |
2017 pullback2017 | -5.97%Dec 2017 | 1mo 17d | 1mo 15d | 3mo 2dOct 2017 - Jan 2018 |
Rate-hike selloffLate 2018 | -5.14%Oct 2018 | 1d | 2mo 10d | 2mo 11dOct 2018 - Jan 2019 |
2018 pullback2018 | -1.79%Feb 2018 | 1mo 2d | 3mo 22d | 4mo 24dJan 2018 - Jun 2018 |
Drawdown Indicators
| ORGO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.74% | -56.78% | -41.96% |
Max Drawdown (1Y)Largest decline over 1 year | -65.75% | -9.10% | -56.65% |
Max Drawdown (3Y)Largest decline over 3 years | -65.75% | -18.90% | -46.85% |
Max Drawdown (5Y)Largest decline over 5 years | -89.00% | -25.43% | -63.57% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.38% | -1.80% | -96.58% |
Average DrawdownAverage peak-to-trough decline | -75.74% | -10.71% | -65.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 39.35% | 2.03% | +37.32% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Organogenesis Holdings Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Organogenesis Holdings Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ORGO relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ORGO has a P/S ratio of 0.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ORGO in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ORGO has a P/B value of 2.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ORGO
Add Organogenesis Holdings Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ORGO